Perspective Therapeutics, Inc. (CATX)
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
$3.13+0.32%
Close 2026-09-04 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · CATX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 49.0% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -89.8% |
Growth built into the price is above our model estimate.
The price assumes 138.8 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
CATX — earnings miss
Dated 2026-03-16
The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after…
Why it matters: Earnings results will show if the company can manage operating losses better. This is key for future funding.
Worry ifOperating income improves to less than -$25M in Q2 2026.
Less concerning ifOperating income worsens to more than -$30M in Q2 2026.
Why it matters: Finishing the site is important for increasing production and helping clinical trials. This affects future revenue.
Supportive ifThe Chicago site will be done by early 2027. This will allow for more production.
Worry ifConstruction delays will push completion past early 2027. This will limit production.
Why it matters: Funding clinical milestones is crucial for the company's growth plans. Progress here signals confidence in future products.
Supportive ifManagement shares news about new funding or partnerships. This will help clinical goals until late 2027.
Worry ifThere are no news or delays in funding for clinical goals until late 2027.
Why it matters: Updates on cash reserves will show if the company can fund trials and operations.
Worry ifCash and equivalents are enough to fund operations until late 2027.
Less concerning ifCash reserves fall below the level needed to fund operations into late 2027.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$236 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $793 loss on $10,000 · 7.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,884 loss on $10,000 · 58.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Ongoing losses hurt the company's money. Improvement shows better control of costs.
Supportive ifOperating losses in Q3 are much lower than in previous quarters.
Worry ifOperating losses in Q3 stay the same or get worse.
Why it matters: Patient recruitment progress will indicate the trial's momentum. This could impact future treatment options for solid tumors.
Watch forCohort 3 of the PSV359 trial shows recruitment of at least 10 patients by late 2026.
Also watch forCohort 3 of the PSV359 trial shows recruitment of fewer than 10 patients by late 2026.
Why it matters: This data shows how well the treatment works for neuroendocrine tumors. Good results could help get regulatory approval.
Supportive ifInterim data shows at least 50% of patients in Cohort 2 have stable disease or better.
Worry ifInterim data shows less than 50% of patients in Cohort 2 have stable disease or better.
Why it matters: Activating sites for the Phase 3 study is key to advancing the lead program. It shows regulatory alignment and readiness for broader trials.
Supportive ifClinical sites for the VMT-α-NET Phase 3 study will be active by December 2026.
Worry ifIf no sites are active by year-end 2026, there may be delays.
Why it matters: New data could provide insights into the efficacy and safety of VMT-α-NET. Positive results may boost investor confidence.
Watch forA presentation shows big gains in effectiveness or safety for VMT-α-NET.
Also watch forA presentation shows safety problems or no gains compared to past data.
Why it matters: Updates on cash reserves show if the company can fund trials and operations. This matters to investors.
Watch forCash, cash equivalents, and short-term investments are more than $237 million.
Also watch forCash reserves are less than $200 million. This raises worries about funding clinical goals.